Aneuploidy and genetic instability in cancer

Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma.

Gastro hep advances·2024

An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.

Science translational medicine·2024

Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.

Science (New York, N.Y.)·2020

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Cancer discovery·2019

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.

Cancer discovery·2019

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.

Leukemia·2019

Clonal dynamics on the road to hematological malignancy (MBL, MGUS, CH).

Seminars in cancer biology·2026

Evolutionary and resistance dynamics in oligometastatic and oligoprogressive cancer treated with stereotactic radiotherapy and systemic therapies: A systematic review and focused meta-analysis.

Seminars in cancer biology·2026

Beyond the traditional dish: Advanced 3D ex vivo culture platforms for tumor modelling.

Seminars in cancer biology·2026

Interplay between DNA and RNA methylation shapes cancer cell plasticity.

Seminars in cancer biology·2026

Role of oral microbiome in cancer immunotherapy.

Seminars in cancer biology·2026

Unveiling tumor heterogeneity by single cell RNA-sequencing: From basic considerations to clinical applications.

Seminars in cancer biology·2026

Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma.

The Laryngoscope·2026

Germline predisposition and somatic mutational landscape in synchronous mucinous metaplasia and neoplasia of the female genital tract.

Clinical and translational medicine·2026

Cystic Fibrosis and Colorectal Cancer Risk: Reprogramming of the Intestinal Epithelial Niche and Cell-State Plasticity in the CFTR Modulator Era.

Cell proliferation·2026

Related Experiment Videos

Aneuploidy and genetic instability in cancer

Related Concept Videos

Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma.

An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.

Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.

Clonal dynamics on the road to hematological malignancy (MBL, MGUS, CH).

Evolutionary and resistance dynamics in oligometastatic and oligoprogressive cancer treated with stereotactic radiotherapy and systemic therapies: A systematic review and focused meta-analysis.

Beyond the traditional dish: Advanced 3D ex vivo culture platforms for tumor modelling.

Interplay between DNA and RNA methylation shapes cancer cell plasticity.

Role of oral microbiome in cancer immunotherapy.

Unveiling tumor heterogeneity by single cell RNA-sequencing: From basic considerations to clinical applications.

Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma.

Germline predisposition and somatic mutational landscape in synchronous mucinous metaplasia and neoplasia of the female genital tract.

Cystic Fibrosis and Colorectal Cancer Risk: Reprogramming of the Intestinal Epithelial Niche and Cell-State Plasticity in the CFTR Modulator Era.

Related Experiment Videos

Aneuploidy and genetic instability in cancer

Related Concept Videos

Related Articles